Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of CB-280 in Cystic Fibrosis
NCT04279769Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CB-280 in cystic fibrosis (CF) (5 arms), sponsored by Calithera Biosciences. Primary endpoint: Incidence and severity of Adverse Events (AEs) at Day 28. Started Jul 2020; status: completed.
02
Drugs
CB-280
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04279769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04279769.